ClinicalTrials.gg
CompletedNCT00195663PREMIERUpdated Jul 12, 2013Results posted

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

A Phase 3 interventional study of Adalimumab and Methotrexate in Early Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 123 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-12.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
799
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
9th of 87
799 · median 160
Started
2000
with 3 others
Phase 3
36 of 87
1 open now
Registered
2nd of 87
by date
Lead sponsor
7 of 87
AbbVie (prior sponsor, Abbott)

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 9th largest by enrollment, is one of 4 that started in 2000, is one of 36 in phase 3, and was the 2nd registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy after treatment with adalimumab for up to 10 years.

Read the detailed description

This study had an initial 2-year double-blind treatment period followed by an 8-year open-label extension period, for a total of up to 10 years study duration. The study was designed to assess the potential of adalimumab + methotrexate to improve signs and symptoms of disease and to inhibit radiographic progression in patients with recent onset (disease duration less than 3 years) rheumatoid arthritis not previously treated with methotrexate. Adalimumab is a human anti-tumor necrosis factor (TNF) monoclonal antibody.

03

Conditions studied

  • Early Rheumatoid Arthritis

Keywords

  • Early Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
  • Diagnosis of rheumatoid arthritis (RA) as defined by the 1987-revised American College of Rheumatology (ACR) criteria, with a disease duration less than 3 years, at least 8 swollen joints out of the 66 joints assessed, at least 10 tender joints out of the 68 joints assessed, at least 1 joint erosion or rheumatoid factor (RF) positivity, erythrocyte sedimentation rate (ESR) >= 28 mm/1h or C-reactive protein (CRP) >= 1.5 mg/dl

Exclusion criteria

Exclusion Criteria:

  • Chronic arthritis diagnosed before the age of 16
  • Preceding treatment with MTX, cyclophosphamide, cyclosporin, azathioprine or more than 2 other disease-modifying anti-rheumatic drugs (DMARDs)
  • Subject previously received anti-tumor necrosis factor (TNF) therapy
  • Permanently wheelchair-bound or bedridden patients
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
799 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Participants received adalimumab 40 mg subcutaneous injection once every other week and placebo to methotrexate orally once a week during the 2-year double-blind treatment phase and then adalimumab 40 mg every other week for up to 8 years in the open-label extension.

    Biological: Adalimumab · Drug: Methotrexate placebo

  • Experimental
    Adalimumab + methotrexate

    Participants received adalimumab 40 mg subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.

    Biological: Adalimumab · Drug: Methotrexate

  • Experimental
    Methotrexate

    Participants received placebo to adalimumab subcutaneous injection once every other week and methotrexate orally once a week at a starting dose of 7.5 mg/week (could be escalated up to 20 mg/week) during the 2-year double-blind treatment phase. Participants received adalimumab 40 mg every other week for up to 8 years in the open-label extension phase.

    Drug: Methotrexate · Biological: Adalimumab placebo

Interventions

  • BiologicalAdalimumab

    Also known as: ABT-D2E7, Humira

  • BiologicalAdalimumab placebo
  • DrugMethotrexate placebo
06

What researchers measure

Primary outcomes

  1. Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52

    American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); * Acute phase reactant value (C-Reactive Protein). Participants who withdrew early were considered non-responders.

    Time frame: Baseline and 52 Weeks

  2. Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52

    The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 52 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.

    Time frame: Baseline and Week 52

  2. Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104

    American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.

    Time frame: Baseline and Week 104

  3. Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104

    The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 104 were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline and Week 104

  4. Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 52

    The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health were included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

    Time frame: Week 52

  5. Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.

    Time frame: Baseline and Week 52

  6. Number of Participants With Major Clinical Response After 104 Weeks of Treatment

    Major clinical response was defined as an American College of Rheumatology 70% (ACR70) response for any six continuous months, over 104 weeks of treatment. A participant was a responder if the following criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were non-responders.

    Time frame: Any 6 continuous months from Baseline to Week 104

  7. Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.

    Time frame: Baseline and Week 52

  8. Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76

    American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.

    Time frame: Baseline and Weeks 26 and 76

  9. Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase

    American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.

    Time frame: Baseline and Weeks 26, 52, 76, and 104

  10. Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase

    American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.

    Time frame: Baseline and Weeks 26, 52, 76, and 104

  11. Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.

    Time frame: Baseline and Weeks 12, 26, 76, and 104

  12. Number of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.

    Time frame: Baseline and Weeks 26, 52, 76, and 104

  13. Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase

    The HUI 2/3 is an assessment of various aspects of participants' health and ability to perform various tasks on a day-to-day basis, including reading, seeing, hearing, speaking, general outlook on life, pain/discomfort, ability to walk, use of hands, memory, ability to think/solve, and ability to perform basic activities such as eating, bathing, and dressing. The HUI 2/3 is a combined 15-item questionnaire based on a recall period of the previous 4 weeks. HUI-2 and HUI-3 scores are calculated independently. The HUI-2 score includes 6 attributes: Sensation, Mobility, Emotion, Cognition, Self-Care, and Pain. The HUI-3 score is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition, and Pain. The range of each score is from 0 (dead) to 1 (perfect health). An increase from Baseline indicates improvement.

    Time frame: Baseline and Weeks 26, 52, and 104

  14. Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase

    The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component and items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.

    Time frame: Baseline and Weeks 26 and 104

  15. Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase

    ACR-N is a composite, continuous variable which measures the percentage of improvement from Baseline in individual participants based on the 7 core set variables of the ACR. ACR-N is defined as the smallest percent change from Baseline of 3 measures: tender joint counts (TJC), swollen joint counts (SJC), and the median percent improvement in the 5 remaining measures (Patient's Assessment of Pain, Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Health Assessment Questionnaire - Disability Index \[HAQ-DI\], and C-Reactive Protein). A positive ACR-N value indicates improvement; a negative ACR-N value indicates worsening; ACR-N of 0 indicates no change.

    Time frame: Baseline and Weeks 26, 52, 76, and 104

  16. Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase

    The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Weeks 26, 52, 76, and 104

  17. Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period

    Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion)to 230 (worst). A large increase in erosion score is indicative of worsening, whereas a small change or no change is indicative of inhibition of joint erosion.

    Time frame: Baseline and Weeks 52 and 104

  18. Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period

    Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joint space narrowing (JSN) scores were recorded for each hand/wrist (16 joints) and each forefoot (5 joints) on a 5-point scale (0 = no narrowing; 1 = up to 25% narrowing; 2 = 26-65% narrowing; 3 = 66-99% narrowing; and 4 = complete narrowing). Scores were summed to calculate the total score ranging from 0 (no narrowing) to 168 (maximum narrowing). A large increase in joint narrowing score is indicative of worsening, whereas a small change or no change is indicative of inhibition of JSN.

    Time frame: Baseline and Weeks 52 and 104

  19. Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase

    The number of participants with no worsening in the modified Total Sharp Score (mTSS) and in erosion and joint space narrowing (JSN) scores, where no worsening is defined as a change from Baseline of ≤ 0 in mTSS, erosion score and JSN score, at Weeks 52 and 104. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline and Weeks 52 and 104

  20. Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104

    The number of participants with no erosions at Baseline and no erosions at Weeks 52 and 104, where no erosions and no new erosions are defined as an erosion score = 0. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion) to 230 (worst).

    Time frame: Baseline and Weeks 52 and 104

  21. Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104

    Number of participants with non-involved joints at Baseline and no newly involved joints at Weeks 52 and 104, where involved joints or no newly involved joints are defined as modified Total Sharp Score (mTSS) = 0. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]).

    Time frame: Baseline and Weeks 52 and 104

  22. Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure

    American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For participants randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.

    Time frame: Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.

  23. Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure

    American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.

    Time frame: Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.

  24. Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure

    American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.

    Time frame: Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.

  25. Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.

    Time frame: Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.

  26. Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure

    The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.

  27. Number of Participants With DAS28 < 2.6 and < 3.2 Over 10 Years by Adalimumab Exposure

    The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: After 1, 2, 5, and 10 years of adalimumab exposure

  28. Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years

    The modified TSS (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

    Time frame: Baseline (prior to first study drug treatment) and Years 2 and 10

  29. Number of Participants With No Radiographic Progression Over 10 Years

    The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. The number of participants with change from Baseline ≤ 0.5 and ≤ 0 is reported as a measure of no disease progression.

    Time frame: Baseline (prior to first study drug treatment) and Years 2 and 10.

  30. Composite Score of ACR50 Plus No Change in Modified Total Sharp Score

    Time frame: Year 10

  31. Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure

    A major clinical response was defined as maintenance of an ACR70 response for at least a 6-month continuous period at any time during the study following the first dose of adalimumab. A participant was a responder if the following criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein).

    Time frame: From the first dose of adalimumab (at Week 1 or Week 106 for patients initially randomized to methotrexate in the DB phase) to Year 10

  32. Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure

    The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A decrease in the HAQ-DI score represents an improvement in physical function; a clinically significant improvement is defined as a decrease of least 0.22 from Baseline in the HAQ-DI score. The number of participants with improvement in HAQ-DI of at least 0.22 and 0.5 units from Baseline is reported.

    Time frame: Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.

07

Results

Posted Feb 25, 2010

Participant flow

Patients were enrolled at 94 sites in 15 countries between January 2001 and April 2004.

2-year Double-blind Treatment Period
Participant flow — 2-year Double-blind Treatment Period
MilestoneMethotrexateAdalimumabAdalimumab + Methotrexate
Started257274268
Completed164166196
Not completed9310872
Withdrew: Adverse event212732
Withdrew: Death020
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject151812
Withdrew: Lack of efficacy475213
Withdrew: Protocol violation664
Withdrew: Planned selection criteria010
Withdrew: Recovery101
Withdrew: Administrative reasons329
Open-Label Extension Period
Participant flow — Open-Label Extension Period
MilestoneMethotrexateAdalimumabAdalimumab + Methotrexate
Started155159183
Completed798586
Not completed767497
Withdrew: Adverse event213236
Withdrew: Lost to follow-up926
Withdrew: Recovery022
Withdrew: Protocol violation344
Withdrew: Death222
Withdrew: Withdrawal by subject161522
Withdrew: Lack of efficacy14612
Withdrew: Administrative reasons111113

Outcome measures

PrimaryNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52

American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); * Acute phase reactant value (C-Reactive Protein). Participants who withdrew early were considered non-responders.

Time frame:
Baseline and 52 Weeks
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52118113165
Statistical analysis
  • Methotrexate vs Adalimumab + Methotrexate · Chi-squared, Corrected · p = <0.001 (Statistical tests were performed in a hierarchical manner. If there was a statistically significant difference in favor of adalimumab + MTX combination treatment, the second primary analysis of the modified Total Sharp Score was to be performed.)
PrimaryChange From Baseline in Modified Total Sharp Score (mTSS) at Week 52

The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 52 were scored in a blinded manner. Joints were scored for erosions on a scale from 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale from 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 525.7 ± 12.73.0 ± 11.21.3 ± 6.5
Statistical analysis
  • Methotrexate vs Adalimumab + Methotrexate · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryChange From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52-0.8 ± 0.6-0.8 ± 0.7-1.1 ± 0.6
Statistical analysis
  • Methotrexate vs Adalimumab + Methotrexate · Wilcoxon (Mann-Whitney) · p = <0.001
SecondaryNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104

American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.

Time frame:
Baseline and Week 104
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104110101158
Statistical analysis
  • Methotrexate vs Adalimumab + Methotrexate · Chi-squared · p = < 0.001
SecondaryChange From Baseline in Modified Total Sharp Score (mTSS) at Week 104

The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and Week 104 were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline and Week 104
Reported as:
Mean · units on a scale
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 10410.4 ± 21.75.5 ± 15.81.9 ± 8.3
Statistical analysis
  • Methotrexate vs Adalimumab + Methotrexate · Wilcoxon (Mann-Whitney) · p = < 0.001
SecondaryNumber of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 52

The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, C reactive protein, and general health were included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score \>5.1 indicates high disease activity, a DAS28 score \<3.2 indicates low disease activity, and a DAS28 score \<2.6 indicates clinical remission.

Time frame:
Week 52
Reported as:
Number · participants
Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 52
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 525364115
Statistical analysis
  • Methotrexate vs Adalimumab + Methotrexate · Chi-squared · p = < 0.001
SecondaryChange From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 5212.5 ± 9.612.6 ± 10.016.7 ± 10.2
Statistical analysis
  • Methotrexate vs Adalimumab + Methotrexate · Wilcoxon (Mann-Whitney) · p = < 0.001
SecondaryNumber of Participants With Major Clinical Response After 104 Weeks of Treatment

Major clinical response was defined as an American College of Rheumatology 70% (ACR70) response for any six continuous months, over 104 weeks of treatment. A participant was a responder if the following criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were non-responders.

Time frame:
Any 6 continuous months from Baseline to Week 104
Reported as:
Number · participants
Number of Participants With Major Clinical Response After 104 Weeks of Treatment
participantsMethotrexate WeeklyAdalimumabAdalimumab + Methotrexate
Number of Participants With Major Clinical Response After 104 Weeks of Treatment7067130
Statistical analysis
  • Methotrexate Weekly vs Adalimumab + Methotrexate · Chi-squared · p = < 0.001
SecondaryChange From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 526.5 ± 11.07.1 ± 12.37.2 ± 13.1
Statistical analysis
  • Methotrexate vs Adalimumab + Methotrexate · Wilcoxon (Mann-Whitney) · p = 0.5402
SecondaryNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76

American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.

Time frame:
Baseline and Weeks 26 and 76
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Week 2610496157
Week 76114114161
SecondaryNumber of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase

American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.

Time frame:
Baseline and Weeks 26, 52, 76, and 104
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Week 26158146184
Week 52161149195
Week 76154137185
Week 104144135186
SecondaryNumber of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase

American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Participants withdrawing early were considered non-responders.

Time frame:
Baseline and Weeks 26, 52, 76, and 104
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Week 265754114
Week 527071122
Week 767579127
Week 1047377125
SecondaryChange From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.

Time frame:
Baseline and Weeks 12, 26, 76, and 104
Reported as:
Mean · units on a scale
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Week 12 [N=236, 246, 252]-0.6 ± 0.6-0.6 ± 0.6-0.8 ± 0.6
Week 26 [N=217, 222, 240]-0.8 ± 0.6-0.8 ± 0.7-0.9 ± 0.6
Week 76 [N= 176, 175, 207]-0.8 ± 0.6-0.9 ± 0.7-1.0 ± 0.7
Week 104 [166, 162, 201]-0.9 ± 0.6-0.9 ± 0.6-1.0 ± 0.7
SecondaryNumber of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.

Time frame:
Baseline and Weeks 26, 52, 76, and 104
Reported as:
Number · participants
Number of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Week 26172169200
Week 52158151186
Week 76144145173
Week 104137132171
SecondaryChange From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase

The HUI 2/3 is an assessment of various aspects of participants' health and ability to perform various tasks on a day-to-day basis, including reading, seeing, hearing, speaking, general outlook on life, pain/discomfort, ability to walk, use of hands, memory, ability to think/solve, and ability to perform basic activities such as eating, bathing, and dressing. The HUI 2/3 is a combined 15-item questionnaire based on a recall period of the previous 4 weeks. HUI-2 and HUI-3 scores are calculated independently. The HUI-2 score includes 6 attributes: Sensation, Mobility, Emotion, Cognition, Self-Care, and Pain. The HUI-3 score is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition, and Pain. The range of each score is from 0 (dead) to 1 (perfect health). An increase from Baseline indicates improvement.

Time frame:
Baseline and Weeks 26, 52, and 104
Reported as:
Mean · units on a scale
Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
HUI-2: Week 26 [N=192, 187, 205]0.2 ± 0.20.2 ± 0.20.2 ± 0.2
HUI-2: Week 52 [N=179, 162, 189]0.2 ± 0.20.2 ± 0.20.2 ± 0.2
HUI-2: Week 104 [N=152, 136, 174]0.2 ± 0.20.2 ± 0.20.2 ± 0.2
HUI-3: Week 26 [N=192, 189, 205]0.3 ± 0.30.3 ± 0.30.3 ± 0.3
HUI-3: Week 52 [N=177, 164, 190]0.3 ± 0.30.3 ± 0.30.4 ± 0.3
HUI-3: Week 104 [N=154, 138, 177]0.3 ± 0.20.4 ± 0.30.4 ± 0.3
SecondaryChange From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase

The SF-36 determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component and items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); increases from Baseline indicate improvement.

Time frame:
Baseline and Weeks 26 and 104
Reported as:
Mean · units on a scale
Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Physical Component: Week 26 [N=199, 204, 221]11.2 ± 10.010.8 ± 10.214.7 ± 10.2
Physical Component: Week 104 [160, 157, 189]12.4 ± 10.313.4 ± 9.716.8 ± 11.2
Mental Component: Week 26 [N=199, 204, 221]7.0 ± 11.65.2 ± 13.56.3 ± 12.1
Mental Component: Week 104 [N=160, 157, 189]8.1 ± 10.96.6 ± 13.56.8 ± 12.0
SecondaryNumeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase

ACR-N is a composite, continuous variable which measures the percentage of improvement from Baseline in individual participants based on the 7 core set variables of the ACR. ACR-N is defined as the smallest percent change from Baseline of 3 measures: tender joint counts (TJC), swollen joint counts (SJC), and the median percent improvement in the 5 remaining measures (Patient's Assessment of Pain, Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Health Assessment Questionnaire - Disability Index \[HAQ-DI\], and C-Reactive Protein). A positive ACR-N value indicates improvement; a negative ACR-N value indicates worsening; ACR-N of 0 indicates no change.

Time frame:
Baseline and Weeks 26, 52, 76, and 104
Reported as:
Mean · percent change
Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase
percent changeMethotrexateAdalimumabAdalimumab + Methotrexate
Week 26 [N=218, 224, 244]44.7 ± 42.239.1 ± 43.357.0 ± 42.2
Week 52 [N=194, 193, 220]50.2 ± 48.244.4 ± 52.266.3 ± 34.8
Week 76 [N=181, 179, 211]56.1 ± 38.151.5 ± 56.868.8 ± 31.3
Week 104 [N=168, 167, 203]57.3 ± 37.154.0 ± 42.771.4 ± 31.0
SecondaryChange From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase

The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Weeks 26, 52, 76, and 104
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Week 26 [N=209, 218, 229]-2.6 ± 1.3-2.4 ± 1.4-3.2 ± 1.3
Week 52 [N=184, 185, 206]-2.8 ± 1.4-2.8 ± 1.5-3.6 ± 1.3
Week 76 [N=173, 173, 197]-3.1 ± 1.2-3.0 ± 1.5-3.7 ± 1.3
Week 104 [N=161, 158, 191]-3.1 ± 1.4-3.2 ± 1.4-3.8 ± 1.3
SecondaryChange From Baseline in Joint Erosion Score During the Double-blind Treatment Period

Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion)to 230 (worst). A large increase in erosion score is indicative of worsening, whereas a small change or no change is indicative of inhibition of joint erosion.

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Mean · units on a scale
Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Week 523.7 ± 8.41.7 ± 5.70.8 ± 3.3
Week 1046.4 ± 14.33.0 ± 8.31.0 ± 4.7
SecondaryChange From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period

Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joint space narrowing (JSN) scores were recorded for each hand/wrist (16 joints) and each forefoot (5 joints) on a 5-point scale (0 = no narrowing; 1 = up to 25% narrowing; 2 = 26-65% narrowing; 3 = 66-99% narrowing; and 4 = complete narrowing). Scores were summed to calculate the total score ranging from 0 (no narrowing) to 168 (maximum narrowing). A large increase in joint narrowing score is indicative of worsening, whereas a small change or no change is indicative of inhibition of JSN.

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Mean · units on a scale
Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Week 522.0 ± 6.31.3 ± 6.60.5 ± 4.2
Week 1044.0 ± 10.92.6 ± 9.50.9 ± 5.1
SecondaryNumber of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase

The number of participants with no worsening in the modified Total Sharp Score (mTSS) and in erosion and joint space narrowing (JSN) scores, where no worsening is defined as a change from Baseline of ≤ 0 in mTSS, erosion score and JSN score, at Weeks 52 and 104. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Number · participants
Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Modified Total Sharp Score: Week 5278112141
Modified Total Sharp Score: Week 10470105136
Erosion Scoe: Week 5291133158
Erosion Score: Week 10481121148
Joint Space Narrowing Score: Week 52127159190
Joint Space Narrowing Score: Week 104112147175
SecondaryNumber of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104

The number of participants with no erosions at Baseline and no erosions at Weeks 52 and 104, where no erosions and no new erosions are defined as an erosion score = 0. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints on each hand/wrist (17 joints) and each forefoot (6 joints) were scored for erosions on a scale of 0 = no erosions; 1 = 1 discrete erosion or ≤20% joint involvement; 2 = 2 separate quadrants with erosion or 21-40% joint involvement; 3 = 3 separate quadrants with erosion or 41-60% joint involvement; 4 = all 4 quadrants with erosion or 61-80% joint involvement; and 5 = extensive destruction with \>80% joint involvement. Scores were summed to calculate the total erosion score, which ranges from 0 (no erosion) to 230 (worst).

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Number · participants
Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Week 5281013
Week 1047811
SecondaryNumber of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104

Number of participants with non-involved joints at Baseline and no newly involved joints at Weeks 52 and 104, where involved joints or no newly involved joints are defined as modified Total Sharp Score (mTSS) = 0. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]).

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Number · participants
Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Week 524912
Week 104379
SecondaryNumber of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure

American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in tender joint count; * ≥ 20% improvement in swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For participants randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.

Time frame:
Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Reported as:
Number · participants
Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure
participantsAny Adalimumab
Year 1 [N=410]340
Year 2 [N=385]332
Year 5 [N=325]231
Year 10 [N=170]154
SecondaryNumber of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure

American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 50% improvement in tender joint count; * ≥ 50% improvement in swollen joint count; and * ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.

Time frame:
Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Reported as:
Number · participants
Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure
participantsAny Adalimumab
Year 1 [N=410]269
Year 2 [N=385]266
Year 5 [N=325]194
Year 10 [N=170]127
SecondaryNumber of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure

American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein). Baseline is the last value prior to the first dose of adalimumab. For patients randomized to the methotrexate (MTX) arm in the double-blind (DB) phase, Baseline was the last visit prior to the first adalimumab dose at Week 106 of the open-label (OL) phase.

Time frame:
Baseline and after 1, 2, 5, and 10 years of adalimumab exposure. Baseline was the last value prior to the first dose of adalimumab.
Reported as:
Number · participants
Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure
participantsAny Adalimumab
Year 1 [N=410]186
Year 2 [N=385]207
Year 5 [N=325]153
Year 10 [N=170]102
SecondaryChange From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative mean changes from Baseline in the overall score indicate improvement.

Time frame:
Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.
Reported as:
Mean · units on a scale
Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure
units on a scaleAny Adalimumab
Year 1 [N=407]-0.9 ± 0.68
Year 2 [N=390]-0.9 ± 0.70
Year 5 [N=344]-0.7 ± 0.73
Year 10 [N=170]-0.9 ± 0.73
SecondaryChange From Baseline in DAS28 Over 10 Years by Adalimumab Exposure

The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.
Reported as:
Mean · units on a scale
Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure
units on a scaleAny Adalimumab
Year 1 [N=403]-3.2 ± 1.49
Year 2 [N=386]-3.3 ± 1.61
Year 5 [N=330]-2.8 ± 1.93
Year 10 [N=158]-3.9 ± 1.29
SecondaryNumber of Participants With DAS28 < 2.6 and < 3.2 Over 10 Years by Adalimumab Exposure

The DAS28 is a composite score of rheumatoid arthritis disease activity derived from the following variables: * 28 tender joint counts, * 28 swollen joint counts, * C-reactive protein, and * Patient's global assessment of disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
After 1, 2, 5, and 10 years of adalimumab exposure
Reported as:
Number · participants
Number of Participants With DAS28 < 2.6 and < 3.2 Over 10 Years by Adalimumab Exposure
participantsAdalimumab: DAS28 < 2.6Adalimumab: DAS28 < 3.2
Year 1 [N=405]173244
Year 2 [N=389]215271
Year 5 [N=333]190244
Year 10 [N=159]109135
SecondaryChange From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years

The modified TSS (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement.

Time frame:
Baseline (prior to first study drug treatment) and Years 2 and 10
Reported as:
Mean · units on a scale
Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years
units on a scaleMethotrexateAdalimumabAdalimumab + Methotrexate
Year 2 [N=83, 92, 89]6.3 ± 12.445.1 ± 9.630.3 ± 3.00
Year 10 [N= 83, 93, 90]10.8 ± 20.019.2 ± 15.213.9 ± 9.64
SecondaryNumber of Participants With No Radiographic Progression Over 10 Years

The modified Total Sharp Score (mTSS) is a measure of change in joint health. Digitized images of radiographs of hands and feet obtained at screening and during the study were scored in a blinded manner. Joints were scored for erosions on a scale of 0 (no damage) to 5 (complete collapse) and joint space narrowing on a scale of 0 (no damage) to 4 (ankylosis or complete dislocation). Erosion scores and narrowing scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). An increase in mTSS from Baseline represents disease progression and/or joint worsening, no change represents halting of disease progression, and a decrease represents improvement. The number of participants with change from Baseline ≤ 0.5 and ≤ 0 is reported as a measure of no disease progression.

Time frame:
Baseline (prior to first study drug treatment) and Years 2 and 10.
Reported as:
Number · participants
Number of Participants With No Radiographic Progression Over 10 Years
participantsMethotrexateAdalimumabAdalimumab + Methotrexate
Change ≤ 0.5 at Year 2 [N=83, 92, 89]364065
Change ≤ 0.5 at Year 10 [N=83, 93, 90]262233
Change ≤ 0 at Year 2 [N=83, 92, 89]223051
Change ≤ 0 at Year 10 [N=83, 93, 90]191629
SecondaryComposite Score of ACR50 Plus No Change in Modified Total Sharp Score
Time frame:
Year 10

No measurements were reported for this outcome.

SecondaryNumber of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure

A major clinical response was defined as maintenance of an ACR70 response for at least a 6-month continuous period at any time during the study following the first dose of adalimumab. A participant was a responder if the following criteria for improvement from Baseline were met: * ≥ 70% improvement in tender joint count; * ≥ 70% improvement in swollen joint count; and * ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); * Patient's global assessment of disease activity (measured on a 100 mm VAS); * Physician's global assessment of disease activity (measured on a 100 mm VAS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * Acute phase reactant value (C-Reactive Protein).

Time frame:
From the first dose of adalimumab (at Week 1 or Week 106 for patients initially randomized to methotrexate in the DB phase) to Year 10
Reported as:
Number · participants
Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure
participantsAny Adalimumab
Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure273
SecondaryNumber of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure

The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A decrease in the HAQ-DI score represents an improvement in physical function; a clinically significant improvement is defined as a decrease of least 0.22 from Baseline in the HAQ-DI score. The number of participants with improvement in HAQ-DI of at least 0.22 and 0.5 units from Baseline is reported.

Time frame:
Baseline and Years 1, 2, 5, and 10. Baseline was the last value prior to the first dose of adalimumab. For patients randomized to the MTX arm in the DB phase, Baseline was the last visit prior to the first adalimumab dose at Week 106.
Reported as:
Number · participants
Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure
participantsAdalimumab: HAQ Decrease ≥ 0.22Adalimumab: HAQ Decrease ≥ 0.5
Year 1 [N=407]353285
Year 2 [N=390]324265
Year 5 [N=344]239188
Year 10 [N=170]140112

Adverse events

Collected over For the double-blind treatment phase, up to 2 years (Methotrexate, Adalimumab and Adalimumab + Methotrexate reporting groups). For the Any Adalimumab reporting group, adverse events include the open-label extension, and are reported for up to 10 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Methotrexate—47/257 (18.3%)227/257 (88.3%)
Adalimumab—65/274 (23.7%)227/274 (82.8%)
Adalimumab + Methotrexate—56/268 (20.9%)241/268 (89.9%)
Any Adalimumab—320/697 (45.9%)634/697 (91%)
Most frequent serious events
Showing 10 of 386
Most frequent serious events
EventMethotrexateAdalimumabAdalimumab + MethotrexateAny Adalimumab
Rheumatoid arthritisMusculoskeletal and connective tissue disorders6/25716/2743/26838/697
OsteoarthritisMusculoskeletal and connective tissue disorders2/2573/2742/26823/697
PneumoniaInfections and infestations1/2570/2742/26815/697
ArthralgiaMusculoskeletal and connective tissue disorders0/2574/2740/2687/697
Atrial fibrillationCardiac disorders0/2571/2741/2688/697
CholelithiasisHepatobiliary disorders0/2572/2743/2688/697
Foot deformityMusculoskeletal and connective tissue disorders0/2572/2741/2688/697
Myocardial infarctionCardiac disorders0/2571/2740/2687/697
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2570/2740/2687/697
SyncopeNervous system disorders2/2570/2741/2687/697
Most frequent other events
Showing 10 of 59
Most frequent other events
EventMethotrexateAdalimumabAdalimumab + MethotrexateAny Adalimumab
NasopharyngitisInfections and infestations63/25762/27481/268219/697
Rheumatoid arthritisMusculoskeletal and connective tissue disorders38/25743/27426/268189/697
Upper respiratory tract infectionInfections and infestations47/25724/27450/268176/697
HeadacheNervous system disorders42/25759/27455/268155/697
HypertensionVascular disorders32/25725/27429/268153/697
NauseaGastrointestinal disorders53/25748/27446/268131/697
Urinary tract infectionInfections and infestations22/25730/27421/268132/697
ArthralgiaMusculoskeletal and connective tissue disorders29/25734/27430/268129/697
DiarrhoeaGastrointestinal disorders42/25732/27428/268105/697
SinusitisInfections and infestations17/25723/27429/268111/697

Baseline characteristics

Age Continuous
Age Continuous(years)MethotrexateAdalimumabAdalimumab + MethotrexateTotal
Mean52.0 ± 13.152.1 ± 13.551.9 ± 14.052.0 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)MethotrexateAdalimumabAdalimumab + MethotrexateTotal
Female190212193595
Male676275204
08

Study locations

123 sites
  • Site Reference ID/Investigator# 322
    Scottsdale, Arizona 85260, United States
  • Site Ref # / Investigator 95957
    La Jolla, California 92037, United States
  • Site Reference ID/Investigator# 429
    La Jolla, California 92037, United States
  • Site Reference ID/Investigator# 2491
    Los Angeles, California 90048, United States
  • Site Reference ID/Investigator# 2500
    Denver, Colorado 80230, United States
  • Site Reference ID/Investigator# 762
    Aventura, Florida 33180, United States
  • Site Reference ID/Investigator# 328
    Sarasota, Florida 34239, United States
  • Site Reference ID/Investigator# 327
    Tampa, Florida 33614, United States
  • Site Reference ID/Investigator# 325
    Zephyrhills, Florida 33542, United States
  • Site Reference ID/Investigator# 302
    Rockford, Illinois 61103, United States
  • Site Reference ID/Investigator# 319
    Cumberland, Maryland 21502, United States
  • Site Ref # / Investigator 95960
    Hagerstown, Maryland 21740, United States
  • Site Reference ID/Investigator# 326
    Wheaton, Maryland 20902, United States
  • Site Reference ID/Investigator# 2533
    Worcester, Massachusetts 01605-0000, United States
  • Site Reference ID/Investigator# 336
    Lincoln, Nebraska 68516, United States
  • Site Reference ID/Investigator# 318
    Concord, New Hampshire 03301, United States
  • Site Reference ID/Investigator# 488
    Durham, North Carolina 27704, United States
  • Site Reference ID/Investigator# 314
    Dayton, Ohio 45408, United States
  • Site Reference ID/Investigator# 761
    Oklahoma City, Oklahoma 73103, United States
  • Site Reference ID/Investigator# 757
    Eugene, Oregon 97401, United States
  • Site Reference ID/Investigator# 361
    Lake Oswego, Oregon 97035, United States
  • Site Reference ID/Investigator# 316
    Bethlehem, Pennsylvania 18015, United States
  • Site Reference ID/Investigator# 4649
    Duncansville, Pennsylvania 16635, United States
  • Site Ref # / Investigator 96122
    Austin, Texas 78705, United States
  • Site Reference ID/Investigator# 306
    Austin, Texas 78705, United States
  • Site Reference ID/Investigator# 313
    Austin, Texas 78705, United States
  • Site Reference ID/Investigator# 2437
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 2532
    Houston, Texas 77074, United States
  • Site Reference ID/Investigator# 758
    Houston, Texas 77074, United States
  • Site Reference ID/Investigator# 321
    Spokane, Washington 99204, United States
  • Site Reference ID/Investigator# 305
    Yakima, Washington 98902, United States
  • Site Reference ID/Investigator# 310
    Brisbane, 4102, Australia
  • Site Reference ID/Investigator# 755
    Camperdown, 2050, Australia
  • Site Reference ID/Investigator# 337
    Clayton, 3168, Australia
  • Site Reference ID/Investigator# 331
    Darlinghurst, Sydney, 2010, Australia
  • Site Reference ID/Investigator# 745
    Kogarah, 2217, Australia
  • Site Reference ID/Investigator# 738
    Maroochydore, 4558, Australia
  • Site Reference ID/Investigator# 335
    New Lambton, 2305, Australia
  • Site Reference ID/Investigator# 737
    Shenton Park, 6008, Australia
  • Site Reference ID/Investigator# 307
    South Hobart, 7004, Australia
  • Site Reference ID/Investigator# 427
    West Heidelberg, 3081, Australia
  • Site Reference ID/Investigator# 739
    Woodville, 5011, Australia
  • Site Reference ID/Investigator# 344
    Vienna, 1090, Austria
  • Site Reference ID/Investigator# 753
    Brussels, 1070, Belgium
  • Site Reference ID/Investigator# 308
    Brussels, 1090, Belgium
  • Site Reference ID/Investigator# 752
    Brussels, 1200, Belgium
  • Site Reference ID/Investigator# 748
    Diepenbeek, 3590, Belgium
  • Site Reference ID/Investigator# 6136
    Ghent, 9000, Belgium
  • Site Ref # / Investigator 98256
    Leuven, 3000, Belgium
  • Site Reference ID/Investigator# 333
    Liege, 4000, Belgium
  • Site Ref # / Investigator 98199
    North York, Ontario M3H 5Y8, Canada
  • Site Reference ID/Investigator# 4646
    Edmonton, T6G 2S2, Canada
  • Site Reference ID/Investigator# 303
    Hamilton, L8N 1Y2, Canada
  • Site Reference ID/Investigator# 330
    Hamilton, L8N 2B6, Canada
  • Site Reference ID/Investigator# 4634
    Montreal, H2L 1S6, Canada
  • Site Reference ID/Investigator# 311
    Montreal, H3Z 2Z3, Canada
  • Site Reference ID/Investigator# 309
    Newmarket, L3Y 3R7, Canada
  • Site Reference ID/Investigator# 304
    Pointe-Claire, H9J 3W3, Canada
  • Site Reference ID/Investigator# 4633
    Richmond, V7C 5L9, Canada
  • Site Reference ID/Investigator# 763
    St. John's, A1A 5E8, Canada
  • Site Reference ID/Investigator# 4635
    Toronto, M4N 3M5, Canada
  • Site Reference ID/Investigator# 490
    Toronto, M5L 3L9, Canada
  • Site Reference ID/Investigator# 760
    Victoria, V8V 3P9, Canada
  • Site Reference ID/Investigator# 4632
    Winnipeg, R3N OK6, Canada
  • Site Reference ID/Investigator# 754
    Hradec Kralove, 500 05, Czech Republic
  • Site Reference ID/Investigator# 332
    Plzen, 305 99, Czech Republic
  • Site Reference ID/Investigator# 734
    Prague 2, 128 50, Czech Republic
  • Site Ref # / Investigator 95878
    Grasten, 6300, Denmark
  • Site Reference ID/Investigator# 6135
    Heinola, FI-18120, Finland
  • Site Ref # / Investigator 6134
    Helsinki, 00029, Finland
  • Site Reference ID/Investigator# 428
    Bobigny, 93009, France
  • Site Reference ID/Investigator# 348
    Montpellier Cedex 5, 34295, France
  • Site Reference ID/Investigator# 4650
    Paris Cedex 14, 75679, France
  • Site Reference ID/Investigator# 3415
    Pierre Benite, 69310, France
  • Site Reference ID/Investigator# 733
    Rennes, 35056, France
  • Site Reference ID/Investigator# 346
    Strasbourg, Cedex 1, 67098, France
  • Site Reference ID/Investigator# 3417
    Berlin-Buch, 13125, Germany
  • Site Reference ID/Investigator# 4631
    Berlin, 10117, Germany
  • Site Reference ID/Investigator# 759
    Berlin, 14059, Germany
  • Site Reference ID/Investigator# 4630
    Erlangen, 91054, Germany
  • Site Reference ID/Investigator# 347
    Freiburg, 79106, Germany
  • Site Reference ID/Investigator# 742
    Goerlitz, 02826, Germany
  • Site Reference ID/Investigator# 746
    Leipzig, 04103, Germany
  • Site Ref # / Investigator 98125
    Munich, 80336, Germany
  • Site Reference ID/Investigator# 339
    Munich, 80336, Germany
  • Site Reference ID/Investigator# 744
    Ratingen, 40882, Germany
  • Site Reference ID/Investigator# 338
    Vogelsang-Gommern, 39245, Germany
  • Site Reference ID/Investigator# 740
    Cork, WDQ-23-KM9, Ireland
  • Site Reference ID/Investigator# 751
    Dublin 4, Ireland
  • Site Ref # / Investigator 95719
    Genoa, 16132, Italy
  • Site Reference ID/Investigator# 323
    Naples, 80131, Italy
  • Site Reference ID/Investigator# 345
    Udine, 33100, Italy
  • Site Reference ID/Investigator# 756
    Verona, 37134, Italy
  • Site Reference ID/Investigator# 343
    Groningen, 9713 GZ, Netherlands
  • Site Reference ID/Investigator# 6133
    Leiden, 2333 ZA, Netherlands
  • Site Reference ID/Investigator# 317
    Maastricht, 6229 HX, Netherlands
  • Site Reference ID/Investigator# 315
    Nijmegen, 6500 HB, Netherlands
  • Site Ref # / Investigator 95800
    Osla, 0027, Norway
  • Site Ref # / Investigator 95875
    Osla, 0370, Norway
  • Site Reference ID/Investigator# 3426
    Piestany, 92112, Slovakia

Showing the first 100 of 123 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Smolen J, Fleischmann R, Aletaha D, Li Y, Zhou Y, Sainsbury I, Galindo IL. Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Res Ther. 2019 Nov 10;21(1):231. doi: 10.1186/s13075-019-2005-9. PubMed 31707982 ↗
  • Smolen JS, van Vollenhoven RF, Florentinus S, Chen S, Suboticki JL, Kavanaugh A. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Ann Rheum Dis. 2018 Nov;77(11):1566-1572. doi: 10.1136/annrheumdis-2018-213502. Epub 2018 Aug 3. PubMed 30076156 ↗
  • Keystone EC, Breedveld FC, Kupper H, Li Y, Florentinus S, Sainsbury I. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis. RMD Open. 2018 Jun 13;4(1):e000637. doi: 10.1136/rmdopen-2017-000637. eCollection 2018. PubMed 29955381 ↗
  • Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017. PubMed 29018564 ↗
  • Moller B, Everts-Graber J, Florentinus S, Li Y, Kupper H, Finckh A. Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial. Arthritis Care Res (Hoboken). 2018 Jun;70(6):861-868. doi: 10.1002/acr.23427. Epub 2018 Apr 25. PubMed 28950430 ↗
  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
  • Landewe R, Smolen JS, Florentinus S, Chen S, Guerette B, van der Heijde D. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Arthritis Res Ther. 2015 May 21;17(1):133. doi: 10.1186/s13075-015-0626-1. PubMed 25994819 ↗
  • Landewe R, Ostergaard M, Keystone EC, Florentinus S, Liu S, van der Heijde D. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Feb;67(2):180-6. doi: 10.1002/acr.22426. PubMed 25073879 ↗
  • Keystone EC, Haraoui B, Guerette B, Mozaffarian N, Liu S, Kavanaugh A. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study. J Rheumatol. 2014 Feb;41(2):235-43. doi: 10.3899/jrheum.121468. Epub 2013 Dec 1. PubMed 24293583 ↗
  • Keystone EC, Breedveld FC, van der Heijde D, Landewe R, Florentinus S, Arulmani U, Liu S, Kupper H, Kavanaugh A. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15. PubMed 24241487 ↗
  • Smolen JS, van der Heijde DM, Keystone EC, van Vollenhoven RF, Goldring MB, Guerette B, Cifaldi MA, Chen N, Liu S, Landewe RB. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2013 Jul;72(7):1156-62. doi: 10.1136/annrheumdis-2012-201620. Epub 2012 Aug 22. Erratum In: Ann Rheum Dis. 2013 Aug;72(8):1432. PubMed 22915617 ↗
  • Strand V, Rentz AM, Cifaldi MA, Chen N, Roy S, Revicki D. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol. 2012 Jan;39(1):63-72. doi: 10.3899/jrheum.101161. Epub 2011 Nov 1. PubMed 22045836 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2000, a primary completion of Apr 2004 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 20, 2005
Start
Dec 2000
Primary completionActual
Apr 2004
CompletionActual
Apr 2012
Results first posted
Feb 25, 2010
Last update
Jul 12, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00195663
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
Dec 2000
Primary completion
Apr 2004
Completion
Apr 2012
Results posted
Feb 25, 2010
Last update
Jul 12, 2013

Study contacts

Dawn Carlson
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Methotrexate

Start the discussion